Stockreport

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

MannKind Corporation  (MNKD) 
Last mannkind corporation earnings: 2/25 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.mannkindcorp.com/press-releases
PDF Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetesPrimary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected [Read more]